227,287 Shares in Alphatec Holdings, Inc. $ATEC Bought by Lisanti Capital Growth LLC

Lisanti Capital Growth LLC bought a new position in shares of Alphatec Holdings, Inc. (NASDAQ:ATEC) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 227,287 shares of the medical technology company’s stock, valued at approximately $3,305,000. Lisanti Capital Growth LLC owned about 0.15% of Alphatec as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the stock. Osterweis Capital Management Inc. acquired a new stake in shares of Alphatec in the second quarter valued at about $37,000. Nisa Investment Advisors LLC boosted its holdings in Alphatec by 22.4% in the second quarter. Nisa Investment Advisors LLC now owns 5,714 shares of the medical technology company’s stock valued at $63,000 after acquiring an additional 1,045 shares during the last quarter. State of Alaska Department of Revenue acquired a new stake in Alphatec during the 3rd quarter valued at approximately $120,000. Destiny Wealth Partners LLC acquired a new stake in Alphatec during the 3rd quarter valued at approximately $145,000. Finally, Park National Corp OH bought a new position in Alphatec during the 3rd quarter worth approximately $147,000. Institutional investors own 66.35% of the company’s stock.

Insider Buying and Selling at Alphatec

In related news, Director David R. Pelizzon sold 250,000 shares of the firm’s stock in a transaction dated Tuesday, December 16th. The shares were sold at an average price of $19.66, for a total value of $4,915,000.00. Following the transaction, the director owned 10,395,045 shares of the company’s stock, valued at approximately $204,366,584.70. This trade represents a 2.35% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director David M. Demski sold 30,000 shares of the business’s stock in a transaction that occurred on Thursday, December 11th. The stock was sold at an average price of $21.20, for a total value of $636,000.00. Following the sale, the director directly owned 399,623 shares of the company’s stock, valued at $8,472,007.60. This represents a 6.98% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 3,233,342 shares of company stock worth $66,688,781 in the last ninety days. 20.90% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the stock. Lake Street Capital set a $25.00 price objective on shares of Alphatec and gave the stock a “buy” rating in a research report on Friday, October 31st. Loop Capital set a $25.00 price target on Alphatec in a report on Wednesday, December 10th. Wall Street Zen raised Alphatec from a “hold” rating to a “buy” rating in a research note on Saturday. JPMorgan Chase & Co. initiated coverage on Alphatec in a research report on Friday, October 24th. They set an “overweight” rating and a $19.00 target price on the stock. Finally, Morgan Stanley set a $23.00 target price on Alphatec in a report on Tuesday, December 2nd. Ten research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $22.82.

Alphatec Stock Performance

Shares of ATEC opened at $14.83 on Friday. Alphatec Holdings, Inc. has a one year low of $8.81 and a one year high of $23.29. The company has a market cap of $2.20 billion, a PE ratio of -14.26 and a beta of 1.01. The stock has a 50-day moving average of $19.65 and a 200-day moving average of $16.88. The company has a debt-to-equity ratio of 43.02, a current ratio of 1.99 and a quick ratio of 1.24.

Alphatec (NASDAQ:ATEC) last announced its quarterly earnings data on Thursday, October 30th. The medical technology company reported $0.03 EPS for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.09. The firm had revenue of $196.50 million during the quarter, compared to analyst estimates of $182.78 million. During the same period last year, the business posted ($0.28) EPS. The company’s revenue was up 30.4% on a year-over-year basis. On average, equities research analysts predict that Alphatec Holdings, Inc. will post -1.08 EPS for the current fiscal year.

Alphatec Company Profile

Alphatec Holdings, Inc (NASDAQ: ATEC) is a medical technology company focused on the design, development and commercialization of products for the surgical correction of degenerative spinal conditions. The company’s portfolio centers on interbody implants, biologics, fixation devices and surgical planning tools intended to improve patient outcomes in spinal fusion procedures. Alphatec’s flagship offerings include customizable interbody cages, bone graft materials and specialized instrumentation designed for minimally invasive and open spinal surgeries.

Founded as Alphatec Spine in 1985 and rebranded as Alphatec Holdings in 2018, the company has grown from a single-product organization into a multi-platform innovator in the spine market.